The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
As mentioned earlier in the week by Bermuda
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.
article
Abstract
Authors
Heather Shaw
Heather Shaw
Mount Vernon Cancer Center
Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Kellati Prasad, Ruth Board, Clare Barlow, James Larkin, Kate Young, Amanda Fitzpatrick, Ioannis Karydis, Maria Marples, Rebecca Lee, Philippa Corrie, Robert Miller, Georgia Goodhew, Fayaz Master, Lindy Durrant
Organizations
Mount Vernon Cancer Center, Nottingham University Hospitals NHS Trust, Churchill Hospital, Velindre Cancer Centre, Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Trust & University of Sheffield, Derriford Hospital, Lancashire University Hospital, Lancashire Teaching Hospitals NHS Trust, Musgrove Park Hospital, Somerset Foundation Trust, The Royal Marsden Hospital NHS Foundation Trust, Royal Marsden Hospital NHS Foundation Trust, Guy’s & St Thomas’ NHS Foundation Trust, University Hospital Southampton NHS Trust, St. James's University Hospital, The Christie NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, Scancell Ltd
Thanks C11,
Just to add that both may prove to have further utility and each will plough it's own furrow so to speak. It is important to remember the development opportunities that may arise from these types of platform. There-in lays the real value me thinks. But first lets get iSCIB1+ validated!
Bermuda, thanks for your reply to my concern!
Violindog,
Sorry, missed your post. Don't worry, the Moderna clinical trial won't have any impact on recruitment to the SCIB1 trial because it's in a different setting and recruiting from a different patient population. Moderna's trial is in the adjuvant setting - patients who have had their tumours surgically removed and are vaccinated to prevent recurrence whereas Scancell's trial is recruiting patients with advanced inoperable melanoma with tumour in situ.
C11 agree with your point room for more than one type of cancer vaccine Heather Shaw referred to “ these will be game changers in immunology “
See Bermuda post on ASCO earlier in the week . Also heather shaw in on the advisory board for the Scope Trial
Skin cancer jab trial targets high-risk melanomas
https://www.thetimes.co.uk/article/e23343c5-91c4-49b0-9fa4-c1eec5c2bb2c?shareToken=6d03ef8920e19e9d3d4fd5f793fc9d06
Dr Heather Shaw, consultant medical oncologist and the national co-ordinating investigator for the trial, said: “I think there is a real hope that these will be the gamechangers in immunotherapy.”
Each patient has their own personalised jab manufactured within weeks, using mRNA genetic code found in their tumours. When injected, the jab instructs the body to create proteins identical to those found on the surface of tumours, triggering an immune response.
From Bermuda shorts
Really good to see that Heather Shaw, one of the SCIB1 study investigators will be presenting a poster at ASCO in Chicago in June.
SCIB1 & iSCIB1+ - Scancell
The abstract title:-
A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label phase 2 SCOPE trial.
Presenter: Heather May Shaw, MD, FRCP, MRCP | Mount Vernon Cancer Center
Abstract: 9535
| Poster Bd #: 319
ASCO isn't just another scientific conference, it's the largest oncology conference in the world and it would have been disappointing if Scancell were not represented.
Chelsea
Absolutely spot on.
IMO, it won’t be a case of either MRNA, or DNA as an available treatment option and there will be room for both as ammo against melanoma. In the same way that there are often multiple treatment options for other diseases. Assuming of course that trial data proves they both work well.
The publicity is positive on a number of fronts. Scancell now need to get their own data published. We already know that should be this year and we’re already in April, so it’s just a handful of months away.
Explains why recruitment has been a little slow....Moderna will be first in the queue!
I like the way the BBC website article has the quote 'you couldn't give this to the next patient in the line because you wouldn't expect it to work.
"It's truly personalised."'
Makes it.sound like an advantage rather than a drawback. If Scancell vaccines come along as hoped, imagine the quotes available for them - ' off the shelf', 'universal' etc.
Just have to wait and see.
I see the story is headline news in some newspapers and contained in that story is Dr Heather Shaw, national co-ordinating investigator for the trial.